

INGA VENTURES PRIVATE LTD.

1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India CIN: U67100MH2018PTC318359 Tel. No.: +91 22 26816003;

Email: foods&inns.oo@ingaventures.com; Contact Person: Kavita Shah; SEBI Registration Number: INM000012698



Pioneer Investcorp Limited

1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai 400 021 CIN: L65990MH1984PLC031909 Tel: +91 22 66186633, E-mail: projectfood@pinc.co.in

Contact Person: Varun Jain SEBI registration no.: INM000002988

August 16, 2024

To.

Foods and Inns Limited

Udyog Bhavan, 2nd Floor 29 Walchand Hirachand Marg, Ballard Estate, Mumbai City, Mumbai, Maharashtra, India -400038

Dear Sir/Madam,

Sub: Submission of Post Offer Advertisement

Ref: Open Offer by Raymond Simkins ("Acquirer 1") and Milan Bhupendra Dalal ("Acquirer 2") (hereinafter Acquirer 1 and Acquirer 2 are collectively referred to as "Acquirers"), along with Borgos Multitrade LLP deemed to be Person Acting In Concert with Acquirer 2 ("PAC") for the purpose of this Open Offer, to the public shareholders of Foods and Inns Limited ("Target Company") for acquisition of upto 1,90,79,617 equity shares of face value of ₹ 1/- each at a price of ₹ 147/- per fully paid up equity share pursuant to regulations 3(1), 4 and other applicable provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended ("SEBI (SAST) Regulations").

This has reference to the captioned offer Open Offer and in terms of Regulation 18(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto ("SEBI (SAST) Regulations"), the Post Offer Advertisement dated August 14, 2024 has been published on August 15, 2024 in the following newspapers:

| Sr. No. | Newspaper | Language | Edition(s) | | |
|------------|-------------------|----------|------------------|--|--|
| 1 | Financial Express | English | All Editions | | |
| 2 | Jansatta | Hindi | All Editions | | |
| 3 | Pratahkal | Marathi | Marathi Editions | | |

We are enclosing herewith a copy of the newspaper clipping of the Post Offer Advertisement published in Financial Express (English).

Kindly take the above information on your record and disseminate the Post Offer Advertisement on the website of Food and Inns Limited.

Thanking you,



INGA VENTURES PRIVATE LTD.

1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India CIN: U67100MH2018PTC318359

Tel. No.: +91 22 26816003; Fax No.: +91 22 26816020; Email: foods&inns.oo@ingaventures.com; Contact Person: Kavita Shah; SEBI Registration Number: INM000012698



Pioneer Investcorp Limited

1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai 400 021 CIN: L65990MH1984PLC031909 Tel: +91 22 66186633,

E-mail: projectfood@pinc.co.in Contact Person: Varun Jain SEBI registration no.: INM000002988

This signature page forms an integral part of this letter in relation to the proposed Open Offer of Foods and Inns Limited

For Inga Ventures Private Limited

Authorized Signatory

Name: Kavita Shah Designation: Partner

Contact number:9867501267 Email:kavita@ingaventures.com

Encl.: As Above



INGA VENTURES PRIVATE LTD.

1229, Hubtown Solaris, N.S. Phadke Marg, Opp. Telli Galli, Andheri (East), Mumbai 400 069, Maharashtra, India CIN: U67100MH2018PTC318359

Tel. No.: +91 22 26816003; Fax No.: +91 22 26816020; Email: foods&inns.oo@ingaventures.com; Contact Person: Kavita Shah; SEBI Registration Number: INM000012698



Pioneer Investcorp Limited

1218, 12th Floor, Maker Chambers V, Nariman Point, Mumbai 400 021 CIN: L65990MH1984PLC031909 Tel: +91 22 66186633,

E-mail: projectfood@pinc.co.in Contact Person: Varun Jain SEBI registration no.: INM000002988

This signature page forms an integral part of this letter in relation to the proposed Open Offer of Foods and Inns Limited

For Pioneer Investcorp Limited

Authorized Signatory Name: Deep Arora

Designation: Assistant Manager Contact number: +91-8961088404 Email: deep.arora@pinc.co.in

Encl.: As Above

Regd, Unit No 101, 1st Floor, KCD Jogesh Eva, Road No.1, Jogeshwari (East), Mumbai – 400 660

Phone: 9137322030 Email: compliance@kcdindustries.com Web: www.kcdindustries.com

| | | dalone | Consolidated Quarter Ended on | | |
|--|---------|----------|----------------------------------|---------|--|
| Particulars | | Ended on | | | |
| Faittedais | | | 30.06.2024 Un-audited | | |
| Total income from operations (net) | 660.857 | 851.055 | 660.857 | 851:055 | |
| Net Profit/(Loss)for a period (before tax, Exceptional and/or Extraordinary items) | 19.329 | 65.374 | 19.329 | 65.374 | |
| Net Profit/(Loss)for a period before tax (after Exceptional and/or Extraordinary items) | 19.329 | 65.374 | 19.329 | 65.374 | |
| Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items) | 13.299 | 65.374 | 13.299 | 65.374 | |
| Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 13.299 | 65.374 | 13.299 | 65.374 | |
| Equity Share Capital | 371.429 | 100 | 371.429 | 100 | |
| Earnings Per Share (of Rs.1 each) (for continuing and discontinued operations) — | | | | | |
| 1. Basic: | 0.047 | 0.654 | 0.047 | 0.654 | |
| 2. Diluted: | 0.047 | 0.654 | 0.047 | 0.654 | |

resum is am extract or the detailed friend of Un-audited Standalone and Consolidated Financial Result ded 30th June 2024 filed with Stock Exchange under Regulation 33 of the SEBI (Listing and Obligati Requiriments) Regulations, 2015. The full format of the quarterly results is available on website o

Sd/-Rajiv Darji Managing Director DIN: 02088219 Date:12th August 2024

POST OFFER ADVERTISEMENT UNDER REGULATION 18 (12) OF SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011, AND AMENOMENTS THERETO FOR THE ATTENTION OF THE PUBLIC SHAREHOLDERS OF

FOODS AND INNS LIMITED

Cin: LS520MH1967PLC013837

Registered Office: Udyog Bhavan, 2" Floor 29 Walchand Hirachand Marg,
Ballard Estate, Mumbai City, Mumbai, Maharashtra, India-400038.

Corporate Office: J. N.; Heredia Marg, Hamilton House, 3" floor,
Ballard Estate, Mumbai, Maharashtra, India, 400038

Contact No: +91 22 2261 3 102

Email ID: cs@foodsandinns.com. Website: https://www.foodsandinns.com/

Den Offer for acquisition of up to 1,907,981 fully paid-up equity shares of face value of \$1 each representing 26,00% of the Expanded Voting Share Capital of Foods and Inns Limited ("Target Company") at a price of \$147 per equity share from the public shareholders of the Target Company") at a price of \$147 per equity share from the public shareholders of the Target Company") at Aprice of \$147 per equity share from the public shareholders of the Target Company by Raymond Simkins ("Acquirer 1") and Milan Bhupendra Dalal ("Acquirer 2") (hereinafter Acquirer 4") at Cleemed to be Person Acting in Concert with Acquirer 2" or "PAC", for the purpose of the Open Offer pursuant to and in compliance with Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto ("SEBI (SAST) Regulations, 2011") ("Open Offer") or "Offer").

This post-offer advertisement ("Post-Offer Advertisement") is issued by Inga Ventures Private Limited and Pioneer Investoorp Limited ("Managers to the Open Offer"), in respect of the Open Offer, for and on behalf of the Acquirers along with the PAC to the Public Shareholders of the Target Company, pursuant to and in compliance with Regulation 18 (12) of SEB (SAST) Regulations, 2011. The detailed public statement dated April 18, 2024 ("Detailed "Public Statement or" or "DS") with respect to the aforementioned Offer was published on April 18, 2024 in the following newspapers:

| Newspaper | Language | Edition(s) | | |
|-------------------|----------|-----------------|--|--|
| Financial Express | English | All Editions | | |
| Jansatta | Hindi | All Editions | | |
| Pratahkal | Marathi | Marathi Edition | | |

The Shareholders of the Target Company are requested to kindly note the following information with respect to the Chee Office:

| Niti | respect to the Open Offer: | | | | | | | |
|------|--|--------|---|-----------------------|-----|------------|--|--|
| 1) | Name of the Target Company | : | Foods and Inns Limited | | | | | |
| 2) | Name of the Acquirer(s) and PAC | : | 1) | Raymond Simkins | 1 | Acquirer 1 | | |
| | | | 2) | Milan Bhupendra Dalal | 20 | Acquirer 2 | | |
| | | | 3) | Borgos Multitrade LLP | 1:1 | PAC | | |
| 3) | Name of the Manager to the Offer | | Inga Ventures Private Limited | | | | | |
| | | | Pioneer Investcorp Limited | | | | | |
| 4) | Name of the Registrar to the Offer | : | Link Intime India Private Limited | | | | | |
| 5) | Offer Details: a) Date of Opening of the Offer b) Date of Closure of the Offer | 27.032 | Tuesday, July 23, 2024 Monday, August 05, 2024 | | | | | |
| 6) | Date of Completion of Payment of Consideration and communication of Rejection/Acceptance | | Friday, August 09, 2024 | | | | | |

7) Details of Acquisition:

| Sr. No. | Particulars | Particulars Proposed in the Letter of Offer ⁽¹⁾ | | | | | |
|------------|--|--|---|--------------------------|--------------------------------------|--|--|
| 7.1 | Offer Price (in ₹) | ₹147 pe | r Equity Share | ₹147 per | Equity Share | | |
| 7.2 | Aggregate number of Shares tendered | | Up to 1,90,79,617(2) | 5,00,712 | | | |
| 7.3 | Aggregate number of Shares accepted | | 5,00,712 | | | | |
| 7.4 | Size of the Offer (Number of Equity Shares multiplied by Offer Price per Equity Share) | ₹280,47,03,699 ⁽³⁾ | | | ₹7,36,04,664 ⁽³⁾ | | |
| 7.5 | Shareholding of the Acquirers before Public Announcement • Number • % of Expanded Voting Share Capital | 81,28,910 11.08% | | | 81,28,910 11.08% | | |
| 7.6 | Shares acquired by way of Agreement / Preferential Allotment Number Meritan Share Capital | | Nii | | | | |
| 7.7 | Shares Acquired by way of Open Offer Number % of Expanded Voting Share Capital | | 1,90,79,617 26% | | | | |
| 7.8 | Shares acquired after Detailed Public Statement ("DPS") Number % of Expanded Voting Share Capital Price of the Shares acquired | | Nii | Nil | | | |
| 7.9 | Post Offer Shareholding of the Acquirers Number By of Expanded Voting Share Capital | 81,28,910 11.08% | | 86,29, 11.7 | | | |
| 7.10 | Pre & Post offer Shareholding of the | Pre-Offer | Post Offer | Pre-Offer | Post Offer | | |
| | Public (other than Acquirers and PAC): Number More Spanded Voting Share Capital | 5,48,83,422 74.79% | 3,58,03,805 ⁽²⁾ 48,79% ⁽¹⁾ | 5,48,83,422 74,79%(1) | 5,43,82,710 74,11% ⁽¹⁾ | | |

- r-ucentages disclosed in the table above are computed basis the Expanded Voling Share Capital. Assuming full acceptance in the Open Offer. Excludes Brukerage and other charges. All the Equity Shares tendered and acquired in the Offer were in dematerialized form and none were in physical form.
- none were in physical form:

 8) The Acquirers, the PAC and its designated Partners accept full responsibility for the information contained in this Post Offer Advertisement and also for the obligations under SEBI (SAST) Regulations, 2011.

 9) A copy of this Post Offer Advertisement will be available on the websites of SEBI (www.sebi.govin), BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.sebi.govin) and will be dispatched to the registered office of the Target Company.

 Capitalized terms used in this Post-Offer Advertisement, but not defined herein, shall have the same meanings assigned to such terms in the Letter of Offer dated July 10, 2024.

Issued by Managers to the Offer on behalf of the Acquirers and the PAC:

Inga Ventures Private Limited
1229, Hubtown Solaris, N.S. Phadke Marg, Opp, Telli Galli,
Andheri (East), Mumbal, 400 069, Maharashtra, India
Tel. No.: -91 12 68510008
Contact Person: Kavita Shah
E-Mail: Foodsandinns.oo@ingaventures.com
SEBI Regn No.: INM000012698

PINC

Pioneer Investcorp Limited 1218, 12º Floor, Maker Chambers V, Nariman Point, Mumbai, 400021 Tel. No.: 1912 26 168633; Contact Person: Varun Jain E-Mail: projectood@pion.co.in SEBI Regn No.: INM000002988

For and on behalf of the Acquirers and PAC

Milan Bhupendra Dalal ("Acquirer 2") Date : August 14, 2024 Place : Mumbai





6 glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026; Corporate Office: Glemmak House, B. D. Sawari Marj, Chakala, Off. Western Express Hayway, Andheri (E), Mumbai - 400099. +91 22 4018 9999 Fax No.: +91 22 4018 9999. Western Express Hayway (E) (1998) Fax No.: +91 22 4018 9999 Fax No.: +91 22 4018 9999 Fax No.: +91 24 4018 999 Fax N

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE. 2024

| 0- | Pr. Albaria | Standalone | | | | Consolidated | | | |
|------------|--|-----------------------|------------------------|-----------------------|------------------------|-----------------------|---|---|-------------------------|
| Sr. No. | Particulars | Quarter ended | Quarter ended | Quarter ended | Year ended | Quarter ended | Quarter ended | Quarter ended | Year ended |
| | | 30/06/2024 | 31/03/2024 | 30/06/2023 | 31/03/2024 | 30/06/2024 | 31/03/2024 | 30/06/2023 | 31/03/2024 |
| _ | Revenue from operations | (Unaudited) | (Refer note 7) | (Unaudited) | (Audited) | (Unaudited) | (Refer note 7) | (Unaudited) | (Audited) |
| ' | (a) Net sales | 22,968.75 | 20,771.32 | 20,980.62 | 76,497.61 | 32,233.02 | 30,160.07 | 29,984.72 | 1,16,354.56 |
| | (b) Other operating income | 326.62 | 710.91 | 463.22 | 2,413.58 | 208.84 | 469.45 | 375.94 | 1,776.41 |
| - 1 | Total revenue from operations | 23,295.37 | 21,482.23 | 21,443.84 | 78,911.19 | 32,441.86 | 30,629.52 | 30,360.66 | 1,18,130.97 |
| 11 | Other income Total income (I + II) | 556.48 23.851.85 | 7,862.70 29.344.93 | 493.61 21.937.45 | 11,680.24 90,591.43 | 314.92 32.756.78 | 7,731.65 38.361.17 | 197.22 30.557.88 | 8,399.94 1,26,530.91 |
| IV | Expenses | 23,031.03 | 29,344.93 | 21,031,43 | 30,331.43 | 32,130.70 | 30,301.17 | 30,337.00 | 1,20,030.91 |
| 5.5 | (a) Cost of materials consumed | 6,481.09 | 6,854.51 | 7,967,56 | 29,904.11 | 6,857.74 | 7,543.09 | 8,302.54 | 31,578.22 |
| | (b) Purchases of stock-in-trade | 889.85 | 816.58 | 821.71 | 3,227.82 | 3,600.26 | 2,108.04 | 4,184.25 | 14,511.70 |
| | (c) Changes in inventories of finished goods, work-in-progress | 569.24 | (21.20) | (230.84) | (1,030.70) | 642.82 | 304.15 | (608.82) | (1,956.22) |
| | and stock-in-trade (d) Employee benefits expense | 3.844.03 | 3.377.45 | 3,344.66 | 14.347.75 | 7,104.40 | 7.009.55 | 6.812.73 | 28.681.43 |
| | (e) Finance costs | 153.49 | 833.85 | 619.34 | 2,771.10 | 395.82 | 1,485.59 | 1,116.08 | 5,159.69 |
| | (f) Depreciation, amortisation and impairment expense | 530.87 | 524.01 | 487.52 | 2,021.62 | 1,177.89 | 1,513.37 | 1,420.40 | 5,819.06 |
| | (g) Other expenses | 5,200,14 | 5,480.41 | 4,690.79 | 20,045.58 | 8,354.51 | 8,621.26 | 7,296,44 | 33,362.53 |
| v | Total expenses (IV) Profit/(loss) before exceptional items and tax (III - IV) | 17,668.71 6,183.14 | 17,865.61 11,479.32 | 17,700.74 4,236.71 | 71,287.28 19,304.15 | 28,133.44 4,623.34 | 28,585.05 9,776.12 | 28,523.62 2,034.26 | 1,17,156.41 9,374.50 |
| vi | Exceptional items (gain)/ loss (Refer note 5) | 0,103.14 | (51,469.13) | 316.29 | (50,703.31) | 4,023.34 | 4,467.85 | 520.23 | 9,009.55 |
| VII | Profit/(loss) before tax from continuing operations | 6,183.14 | 62,948.45 | 3,920.42 | 70,007.46 | 4,623.34 | 5,308.28 | 1,514.03 | 364.95 |
| 772420 | (V - VI) | | | | | | | | |
| VIII | Tax expense : Current tax | 1,079.84 | 10,553.79 | 385.65 | 10,499.92 | 1,468.82 | 10,581.74 | 567.23 | 11,155.52 |
| | Deferred tax | 565.99 | 6,257.71 | 818.21 | 7,834.63 | (247.86) | 7,112.99 | 570.02 | 7,517.93 |
| IX | Profit/(loss) after tax for the period from continuing operations | 4,537.31 | 46,136.95 | 2,716.56 | 51,672.91 | 3,402.38 | (12,386.45) | 376.78 | (18,308.50) |
| | (VII - VIII) | | | | | | 100000000000000000000000000000000000000 | | o-summers 57A |
| Х | Profit/(loss) for the period from continuing operations attributable to: | | | | | | 22.22 | 201.01 | **** |
| | Non-controlling interests Owners of the Company | 4,537.31 | 46,136.95 | 2,716.56 | 51,672.91 | (0.29) | 40.10 (12,426.55) | 231.94 144.84 | 681.46 (18,989.96) |
| XI | Profit/(loss) before tax from discontinued operations | 4,001.01 | 40,130.33 | 2,110.00 | 31,012.31 | 5,402.07 | 310.80 | 1,820.04 | 5.326.92 |
| XII | Tax expense of discontinued operations : | | | | | | 20200 | 1000000 | SMESSIE. |
| | Current tax | | | | | 20 | 72.73 | 435.99 | 1,284.32 |
| XIII | Deferred tax Profit/(loss) after tax for the period from discontinued operations | | | | | | (5.69) 243.76 | 29.55 1,354.50 | 69.32 3,973.28 |
| Alli | (XI - XII) | | | | | - 5 | 243.76 | 1,354.30 | 3,9/3.20 |
| XIV | Profit/(loss) for the period from discontinued operations attributable to: | | | | | | | | |
| | Non-controlling interests | | | | | - | 2000 | 100000000000000000000000000000000000000 | Samuel F |
| 201 | - Owners of the Company | | | | | 0.400.00 | 243.76 | 1,354.50 | 3,973.28 |
| XV | Profit/(loss) after tax for the period from continuing and discontinued operations (IX + XIII) | | | | | 3,402.38 | (12,142.69) | 1,731.28 | (14,335.22) |
| XVI | Profit/(loss) for the period from continuing and discontinued | | | | | | | | |
| | operations attributable to: | | | | | | | | |
| | Non-controlling interests | 4.537.31 | 46.136.95 | 2.716.56 | 51.672.91 | (0.29) | 40.10 | 231.94 | 681.46 |
| XVII | Owners of the Company Other comprehensive income from continuing operations | 4,037.31 | 40,130.95 | 2,710.00 | 51,072.91 | 3,402.67 | (12,182.79) | 1,499.34 | (15,016.68) |
| 2440 | A (i) Items that will not be reclassified to profit or loss | (12.52) | (9.74) | (7.50) | (73.14) | (7.01) | (94.10) | (5.52) | (163.06) |
| | (ii) Income tax relating to items that will not be reclassified to | 4.37 | 9.44 | 2.23 | 25.56 | 2.79 | 26.65 | 2.23 | 42.75 |
| | profit or loss | | | | | | 2000 | 22772 | 7222234 |
| | B (i) Items that will be reclassified to profit or loss (ii) Issues for polyting to items that will be reclassified to profit. | | | × | *) | 60.50 | 846.57 (20.13) | (564.37) 6.80 | (399.03) |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | | 8 | 8 | 8 | (1.36) | (20,10) | 0.00 | (10,01) |
| XVIII | Total comprehensive income from continuing operations for the | 4,529.16 | 46,136.65 | 2,711.29 | 51,625.33 | 3,457.30 | (11,627.47) | (184.08) | (18,907.81) |
| 1004 | period/ year | | | | | | (0.40) | (0.70) | (50.00) |
| XIX | Other comprehensive income from discontinued operations for the period/ year | | | | | | (0.19) | (0.73) | (56.23) |
| XX | Total comprehensive income from discontinued operations for the | | | | | 59 | 243.57 | 1,353.77 | 3,917.05 |
| | period/ year (XIII + XIX) | | | | | | | | |
| XXI | Other comprehensive income for the period/ year from continuing | (8.15) | (0.30) | (5.27) | (47.58) | 54.92 | 758.79 | (561.59) | (655.53) |
| XXII | and discontinued operation (XVII + XIX) Total comprehensive income for the period/year from continuing | 4,529.16 | 46,136,65 | 2,711.29 | 51.625.33 | 3,457.30 | (11,383.89) | 1,169.69 | (14,990.76) |
| 700 | and discontinued operation (XVIII + XX) | 14,020.10 | | 4,717.20 | 01,020,00 | 0,401.00 | (11,000.00) | 1,100.00 | (14,000.10) |
| XXIII | Total comprehensive income attributable to: | | | | | | | | |
| | - Non-controlling interests | 4 500 40 | 20.400.05 | 0.744.00 | C4 007 00 | (0.26) | 40.22 | 231.98 | 672.00 |
| XXIV | Owners of the Company Paid up Equity Share Capital, Equity Shares of Re. 1/- each | 4,529.16 282.19 | 46,136.65 282.19 | 2,711.29 282.17 | 51,625.33 282.19 | 3,457.56 282.19 | (11,424.11) 282.19 | 937.71 282.17 | (15,662.76) 282.19 |
| XXV | Other equity (other than revaluation reserve) | LOLITO | EGE. (C | 202111 | 2,29,424.01 | 3202.10 | 202.10 | | 78,197.08 |
| XXVI | Earning per share for continuing operations (EPS) | | | | | | | | |
| | (not annualised except for the year ended 31 March) | | | | | 40.00 | 744.00 | 0.74 | (07.00) |
| | Basic (in Rupees) Diluted (in Rupees) | | | | | 12.06 12.06 | (44.04) (44.04) | 0.51 0.51 | (67.30) (67.30) |
| XXVII | Earning per share for discontinued operations (EPS) | | | | | 12.00 | (44.04) | 9.91 | (07.30) |
| | (not annualised except for the year ended 31 March) | | | | | | | | |
| | Basic (in Rupees) | | | | | | 0.86 | 4.80 | 14.08 |
| XXVIII | Diluted (in Rupees) | | | | | | 0.86 | 4.80 | 14.08 |
| AAVIII | Earning per share for continuing and discontinued operations (EPS) (not annualised except for the year ended 31 March) | | | | | | | | |
| | Basic (in Rupees) | 16.08 | 163.50 | 9.63 | 183.13 | 12.06 | (43.17) | 5.31 | (53.22) |
| | | 16.08 | 163.50 | 9.63 | 183.12 | 12.06 | (43.17) | 5.31 | (53.22) |

The Financial results have been prepared in accordance with Indian Accounting Standards (Ind. AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 30 of the SEBI Listing Objections and Disclosure Requirements (Regulations, 2015) (as a manufact).

The above results were reviewed by the Audit Committee at its meeting held on 15° August, 2024 and approved by the Board of Directors at their meetings held on 16° August, 2024. The results for the quarter ended 30° June, 2024 presented were subjection for a "Intimate Review" by statistury auditors of the Company who have issued an unmodified report on the sustrement of the Company has only one reportable agent in La Philamanoualical business level, comprising of generics and active pharmacoulical ingredient components, which are interlinked and inter-objected, the Policy on the Company has only one reportable agented, in Philamanoualical business level, comprising of generics and active pharmacoulical ingredient components, which are interlinked and inter-objected, therefore, the Company has only one reportable agented, and a 10° June, 2024, pursuant to Employee Stock Options Scheme 2016, 37,717 options were custainting, which upon exercise are convertible into equivalent number of equity shares.

FINANCIAL EXPRESS

Exceptional terms:
\$1.03.2024
Exceptional term in the standarion result for the quarter and year ended 31 March 2024 Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of exceptional term in the standarion result for inequarter and year ended 31 March 2024 Rs. 51,469.13 million (gain) and Rs 50,703.31 million (gain) respectively, primarily comprises of stake sale (net of exceptional terms (Linescincos Lts, remediation, legal, reventory provision and others.

Parsants bear deep round iduated? Suprise-Part 2023, the Company reference has been excepted by the Body of the Suprise of Rs 51.75 million (gain) and the Suprise of Rs 51.75 million (gain) respectively, primarily comprises of stake sale (net of Rs 51.75 million (gain) present provided and provide

item of Rs.316.29 in the standalone result for the quarter comprises of remediation cost of manufacturing sites in India.

Consolidated:
3.10.3.2024
Exceptional liters in the Consolidated result for the quarter and full year ended 31 March 2024 is Rs. 4.487.85 million (loss) and Rs 0.000 55 million (loss) respectively primary) comprises of stake sale (net of expenses) in Glemanx (Histochenoe Ltd., Impairment of certains block at Morrore facility, De-printinsation of certain intrangibles, settlement & logal cout, emediation cost and working capital adjustments.

The US subsidiary Glemanx Pharmacouticals line. USA (Company) has entered into an agreement with the U.S. Department of Justice, Architect Division (DO) and 22 August. 2023 to resolve all of its court in the DOI working histocherical princing practices relating to the generic drug pravastal between 2013 and 2015. The Company has been deferred Prosecution drug prevaints in the US absidiary (Glemanx Pharmacouticals Inc., USA) (Company) is likely to refer into an agreement with the U.S. Department of Justice, Architect Division (DOI), subject to all necessary approvals being in place, to the extent of \$30 million (including related cost), to resolve all of 16 Civil Court proceedings with the DOI. Due to the non-recurring nature of the provision in this respect.

Exceptional bear in the fundational stements for the quarter and full year ended 31 March 2024 (includes Rs. 3,108.41 million and Rs. 6,884.30 million respectively comprises of the U.S. Department of Justice, Architectural Experiments, the visibilities of the protection in from the Consolidation design of the multi-ching place of provision in this respect.

The Board of Directors of Glemanus Pharmacouticals Inc., USA in their meeting held on 23 May, 2024 decided to migrated the block of OSD & Nebulizer within the manufacturing state of the protection of the provision of the provision of the protection of the protection of the provision of the protection of the Silve Protection of the Silve Protection of the Silve Protection of the

Glemank Pharmaceuticals Limited
Annacuse A
Annacuse A
Annacuse A
Annacuse A
Annacuse A
Annacuse A
List of entities included in the consolidated financial results for the quarter ended 30 June 2024
List of entities included in the consolidated financial results for the quarter ended 30 June 2024
I Sciennar Pharmaceuticals E. A. D. S. Glemank Pharmaceuticals S. R. D. S. Glemank Pharmaceuticals Plays S. A. S. Glemank Pharmaceuticals S. R. D. S. D. C. V. C. Glemank Pharmaceuticals S. R. D. S. D. C. V. C. Glemank Pharmaceuticals Plays S. A. S. Glemank Pharmaceuticals S. C. A. S. Glemank Pharmaceuticals S. R. D. S. C. S. Glemank Pharmaceuticals S. Glemank Pharmaceuticals S. C. S. Glemank Pharmaceuticals S. Glemank Pharm

Glenn Saldanha Chairman & Managing Director Mumbai, 14 August 2024









